A feasibility study of image-guided hypofractionated conformal arc therapy for inoperable patients with localized
Samuel Bral1, Hilde Van Parijs, Guy Soete
1Department of Radiotherapy, University Hospital Brussels (UZB), Brussels, Belgium. samuel.bral@uzbrussel.be
Abstract:
We treated 36 cases of stage I/II non-small cell lung cancer in inoperable patients. Treatments were planned to a total isocenter dose of 60Gy (8x7.5Gy) based on a dynamic field shaping arc, employing one arc to span as much area as possible and if needed additional weighted segments. The 2 year infield progression free probability is 65%. Disease-specific survival is 75% at 2 years. No patients experienced grade 3-4 toxicity.
